Business Wire

Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005966/en/

Gwenan White, Executive Vice President, Communications and Public Affairs, Ipsen (Photo: Business Wire)

Gwenan White, Executive Vice President, Communications and Public Affairs, Ipsen (Photo: Business Wire)

Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Gwenan White as Executive Vice President, Communications and Public Affairs, effective March 2021. Based in Boulogne, France, she will be responsible for designing, implementing and managing the communications and public affairs strategy for Ipsen at global level, reporting directly to David Loew, CEO, Ipsen. Gwenan will serve on the Executive Leadership Team.

“Along with the ELT, we are very pleased to welcome Gwenan to Ipsen. She will be critical to the implementation of our new strategy, Focus. Together. For patients & society. Her background in communications and public affairs will help reinforce Ipsen’s position as partner and employer of choice and will contribute to developing the share-of-voice of our innovative medicines. We look forward to working closely with her,” said David Loew, CEO, Ipsen.

I’m excited to join Ipsen at this key moment,” said Gwenan White. “I look forward to further building Ipsen’s relationships and engagement with institutions and stakeholders worldwide, ensuring the strategic alignment of its communications and boosting the visibility of its brands.”

Prior to joining Ipsen, Gwenan was the Global Head of Pharma Communications and Patient Advocacy at Novartis Pharmaceuticals. Over the course of her career, she has held a variety of roles in public affairs, corporate, science and product communications, patient advocacy and marketing at AbbVie, GSK and Schering Plough.

Gwenan is a graduate of the University of Liverpool in BSc (Hons) Biochemistry in 1990.

She will be based in Boulogne - France.

About Ipsen
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.fr.

Ipsen’s Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group is dependent on prices set for drugs, pricing and reimbursement reforms and is vulnerable to the potential withdrawal of certain drugs from the list of reimbursable products by governments, and the relevant regulatory authorities in its locations. In light of the economic crisis caused by the COVID-19 pandemic, there could be increased pressure on the pharmaceutical industry to lower drug prices. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2019 Universal Registration Document available on its website www.ipsen.com.

Contact information

Media
Fanny Allaire
Global Communications Director
+33(0)1 58 33 58 96
fanny.allaire@ipsen.com

Financial Community
Eugenia Litz
Vice President, Investor Relations
+44 (0) 1753 627721
eugenia.litz@ipsen.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s ESG Solutions Group: V.E Provides Second Party Opinion on Italy’s First Sovereign Green Bond Framework and Issuance25.2.2021 22:33:00 EETPress release

Moody’s ESG Solutions Group announced today that Moody’s affiliate V.E has provided a Second Party Opinion on Italy’s sovereign green bond framework and first green bond issuance. The framework, which is aligned with the four core components of the Green Bond Principles 2018, will be used to finance budget lines reflective of Italy’s environmental priorities, including renewable energy and clean transportation. In V.E’s opinion, these categories are likely to contribute to seven of the United Nations Sustainable Development Goals. “In our assessment, the bonds issued via this framework will provide a ‘robust’ contribution to sustainability. Italy has committed to conduct due diligence on the environmental contribution of the projects that it chooses to finance. The financed expenses have clear benefits in terms of climate mitigation, climate adaptation, pollution prevention and control, transition to a circular economy, the responsible management of natural resources, and the protectio

International Zinc Association Launches Zinc Battery Initiative25.2.2021 21:48:00 EETPress release

The International Zinc Association (IZA) is excited to announce the launch of its newest program, the Zinc Battery Initiative. Recent extreme weather events, amplified by climate change, have once again focused attention on the future role of fossil fuels and the capacity and resilience of energy grids worldwide. One of the most impactful ways of addressing this is through cost-effective energy storage. As renewables become an ever-greater part of the electrical grid, energy storage can help address solar and wind power's intermittency. It can also help respond to large fluctuations in demand by capturing and storing excess energy during low demand and bringing it online during peak times. Energy storage also helps provide resilience by serving as a backup energy supply when generation is interrupted. It will also play a pivotal role in electrifying transport, and other applications where power is needed, but tethered connections to the grid are not practical. Addressing climate change

Hyosung TNS Invites Customers to ‘Be Inspired’ With New Campaign25.2.2021 19:00:00 EETPress release

Hyosung TNS, the world-leading ATM manufacturer, has begun a global initiative to reinvent its user experience through the implementation of a branding refresh titled “Be Inspired.” The campaign draws upon the impressive technological history of the industry innovator to lead clients through a journey to experience solutions-driven communication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005240/en/ Hyosung TNS' technologically impressive, new 140-page website has been designed to unify Hysoung's leadership in the financial institution and retail industries and consolidate all of its previous, regional websites into one global website, including a multi-language interface and an intuitive, interactive product catalog. (Photo: Business Wire) The “Be Inspired” initiative employs “plain language and interaction” that show how Hyosung is inspired by its customers to create new business solutions – and how those solutio

CMT’s New Report Confirms Increasing Appetite for Connected Insurance in Europe25.2.2021 18:25:00 EETPress release

A large shift in driving habits due to the COVID-19 pandemic has changed how people think about motor insurance across Europe, according to a new study by Cambridge Mobile Telematics (CMT), the world’s leading mobile telematics and analytics provider. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005773/en/ (Graphic: Business Wire) Based on the surveys of 4,000 drivers in France, Germany, Italy and the U.K., the new report shows shifting attitudes towards quoting channels, claims services, pricing models and value-added services, broken down and analysed by location, age and driving behaviour. The two surveys - taken in January 2020, before the pandemic, and then nine months later in September 2020 - reveal up to 81 percent of the drivers in Europe have changed how they drive because of COVID-19. Now 65 percent are interested in connected insurance, a 32% jump in nine months. The pandemic has modified commuting patter

Alpega Group Showed Impressive Results In 202025.2.2021 18:00:00 EETPress release

Alpega Group, a leading provider of end-to-end transportation and logistics management software, has positioned itself to meet logistics challenges with impressive results in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005665/en/ Alpega Group, a leading provider of end-to-end transportation and logistics management software, has positioned itself to meet logistics challenges with impressive results in 2020. (Photo: Alpega Group) Alpega’s business units had an outstanding performance last year. On one hand, their freight exchanges’ customer acquisitions strongly grew by 20% compared to the previous year and existing clients had a higher renewal rate. On the other hand Alpega TMS added 83 new customers and had a tremendous increase in usage of their smart booking solution. Alpega’s CEO, Todd DeLaughter, commented on these results: “I’m very excited with Alpega’s excellent performance proving the value of our sol

MyHeritage Releases Groundbreaking Feature to Animate the Faces in Still Photos25.2.2021 17:54:00 EETPress release

MyHeritage, the leading global service for discovering your past and empowering your future, announced today the release of Deep Nostalgia™, a new feature that animates the faces in still photos. Deep Nostalgia™ gives family history a fresh new perspective by producing a realistic depiction of how a person could have moved and looked if they were captured on video. MyHeritage is the only company to offer a complete suite of features for colorizing, restoring, enhancing, and now animating historical photos. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005747/en/ Introducing Deep Nostalgia™ (Photo: Business Wire) The technology for animating the faces in photos was licensed by MyHeritage from D-ID, a company that specializes in video reenactment using deep learning. Deep Nostalgia™ uses several pre-recorded driver videos prepared by MyHeritage, which direct the movements in the animation and consist of sequences of rea

Andersen Global Enhances Caribbean Platform with Baptiste & Co. Law Firm25.2.2021 17:30:00 EETPress release

Further strengthening its Caribbean platform and adding additional coverage in the southern edge of the region, Andersen Global expands into St. Vincent and the Grenadines with collaborating firm Baptiste & Co. Law Firm. Established in 1986, Baptiste & Co. Law Firm, was founded by Managing Partner René M. Baptiste, who possesses more than 40 years of experience. In addition to founding the firm, René’s accomplishments include admission to the Bar in St. Vincent and the Grenadines, Antigua and Barbuda, Saint Kitts and Nevis; published articles in the International Finance journal; two terms of service as an elected member of Parliament and Cabinet Minister in St. Vincent and the Grenadines; and the role of Speaker of the Organization of Eastern Caribbean States’ Assembly. Additionally, she possesses well over 50 years of public service, which has resulted in recognition from Her Majesty Queen Elizabeth II in the form of elevation to Commander of Saint Michael and Saint George (CMG) for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom